EWTX
HealthcareEdgewise Therapeutics, Inc.
$29.45-0.49 (-1.64%)
Prev Close
$29.94
Open
$30.10
High
$31.36
Low
$29.01
Volume
503.8K
Market Cap
$3.14B
P/E
—
Div Yield
—
Over the past 12 months, insider activity at Edgewise Therapeutics, Inc. (EWTX) has been mixed between buying and selling, with 2 insider purchases totaling $10.20M and 16 insider sales totaling $10.88M. The most recent insider transaction was by Edris Badreddin (director), who sold $3.40M worth of shares on Jan 23, 2026. Edgewise Therapeutics, Inc. operates in the Healthcare sector, within the Biotechnology industry, with a market cap of $3.14B.
Buys (12M)
2
$10.20M
Sells (12M)
16
$10.88M
Net Activity
Net Seller
$685.4K
Active Insiders
9
last 12 mo
EWTX Price Chart
EWTX Insider Trading Activity
| Date | Insider | Role | Type | Shares | Avg Price | Value | Shares After |
|---|---|---|---|---|---|---|---|
| Jan 23, 2026↗ | Edris Badreddin | director | Sell | 115,471 | $29.44 | $3.40M | 121,601 |
| Jan 21, 2026↗ | Edris Badreddin | Director | Sell | 115,471 | $29.44 | $3.40M | 0 |
| Nov 12, 2025↗ | Russell Alan J | Chief Scientific Officer | Sell | 100,000 | $21.12 | $2.11M | 0 |
| Nov 11, 2025↗ | Fox Jonathan C | Director | Buy | 10,700 | $18.64 | $199.4K | 0 |
| Aug 26, 2025↗ | Russell Alan J | Chief Scientific Officer | Sell | 100,000 | $14.60 | $1.46M | 0 |
| Aug 12, 2025↗ | Carruthers R Michael | Chief Financial Officer | Sell | 1,428 | $13.39 | $19.1K | 0 |
| Aug 12, 2025↗ | Derakhshan Behrad | Chief Business Officer | Sell | 2,491 | $13.39 | $33.4K | 0 |
| Aug 12, 2025↗ | Donovan Joanne M. | CMO | Sell | 2,862 | $13.39 | $38.3K | 0 |
| Aug 12, 2025↗ | KOCH KEVIN | President and CEO | Sell | 7,972 | $13.39 | $106.8K | 0 |
| Aug 12, 2025↗ | MOORE JOHN R | General Counsel | Sell | 2,098 | $13.39 | $28.1K | 0 |
| Aug 12, 2025↗ | Russell Alan J | Chief Scientific Officer | Sell | 1,907 | $13.39 | $25.5K | 0 |
| May 1, 2025↗ | Carruthers R Michael | Chief Financial Officer | Sell | 1,314 | $16.45 | $21.6K | 0 |
| May 1, 2025↗ | Derakhshan Behrad | Chief Business Officer | Sell | 1,691 | $16.45 | $27.8K | 0 |
| May 1, 2025↗ | Donovan Joanne M. | CMO | Sell | 5,187 | $16.45 | $85.3K | 0 |
| May 1, 2025↗ | KOCH KEVIN | President and CEO | Sell | 4,276 | $16.45 | $70.4K | 0 |
| May 1, 2025↗ | MOORE JOHN R | General Counsel | Sell | 1,930 | $16.45 | $31.8K | 0 |
| May 1, 2025↗ | Russell Alan J | Chief Scientific Officer | Sell | 1,551 | $16.45 | $25.5K | 0 |
| Apr 3, 2025↗ | Thompson Peter A. | Director | Buy | 496,771 | $20.13 | $10.00M | 0 |
| Mar 7, 2025↗ | KOCH KEVIN | President and CEO | Sell | 100 | $30.00 | $3.0K | 0 |
| Mar 7, 2025↗ | Russell Alan J | Chief Scientific Officer | Sell | 200 | $30.02 | $6.0K | 0 |
| Feb 7, 2025↗ | Derakhshan Behrad | Chief Business Officer | Sell | 10,000 | $30.03 | $300.3K | 16,837 |
| Feb 7, 2025↗ | KOCH KEVIN | President and CEO | Sell | 9,536 | $30.13 | $287.3K | 14,478 |
| Feb 7, 2025↗ | Russell Alan J | Chief Scientific Officer | Sell | 9,215 | $30.04 | $276.8K | 14,863 |
| Jan 30, 2025↗ | Donovan Joanne M. | CMO | Sell | 25,000 | $27.63 | $690.7K | 16,358 |
| Dec 31, 2024↗ | Russell Alan J | Chief Scientific Officer | Sell | 100,000 | $27.37 | $2.74M | 14,863 |
| Dec 27, 2024↗ | Semigran Marc | Chief Development Officer | Sell | 29,709 | $29.69 | $881.9K | 8,445 |
| Sep 24, 2024↗ | Carruthers R Michael | Chief Financial Officer | Sell | 125,092 | $28.57 | $3.57M | 35,928 |
| Sep 24, 2024↗ | Derakhshan Behrad | Chief Business Officer | Sell | 42,068 | $29.03 | $1.22M | 15,121 |
| Sep 24, 2024↗ | Donovan Joanne M. | CMO | Sell | 7,162 | $28.29 | $202.6K | 14,538 |
| Sep 24, 2024↗ | MOORE JOHN R | General Counsel | Sell | 70,922 | $28.15 | $2.00M | 3,252 |
| Sep 24, 2024↗ | Russell Alan J | Chief Scientific Officer | Sell | 75,000 | $28.27 | $2.12M | 13,534 |
| May 3, 2024↗ | Carruthers R Michael | Chief Financial Officer | Sell | 2,157 | $18.91 | $40.8K | 35,230 |
| May 3, 2024↗ | Derakhshan Behrad | Chief Business Officer | Sell | 1,718 | $18.91 | $32.5K | 13,422 |
| May 3, 2024↗ | Donovan Joanne M. | CMO | Sell | 3,682 | $18.91 | $69.6K | 19,897 |
| May 3, 2024↗ | KOCH KEVIN | President and CEO | Sell | 3,152 | $18.91 | $59.6K | 14,478 |
| May 3, 2024↗ | MOORE JOHN R | General Counsel | Sell | 1,956 | $18.91 | $37.0K | 3,252 |
| May 3, 2024↗ | Russell Alan J | Chief Scientific Officer | Sell | 1,576 | $18.91 | $29.8K | 7,238 |
| Feb 9, 2024↗ | Derakhshan Behrad | Chief Business Officer | Sell | 10,000 | $20.03 | $200.3K | 7,020 |
| Feb 9, 2024↗ | MOORE JOHN R | General Counsel | Sell | 29,835 | $20.00 | $596.8K | 0 |
| Jan 25, 2024↗ | Carruthers R Michael | Chief Financial Officer | Sell | 90,000 | $15.78 | $1.42M | 29,024 |
| Jan 25, 2024↗ | ORBIMED ADVISORS LLC | Director | Buy | 454,545 | $11.00 | $5.00M | 14,436,500 |
| Jan 25, 2024↗ | Thompson Peter A. | Director | Buy | 454,545 | $11.00 | $5.00M | 14,436,500 |
| Dec 28, 2023↗ | Fox Jonathan C | Buy | 10,857 | $9.30 | $101.0K | 10,857 | |
| Dec 28, 2023↗ | MOORE JOHN R | General Counsel | Sell | 8,497 | $10.50 | $89.2K | 0 |
| Dec 28, 2023↗ | Russell Alan J | Chief Scientific Officer | Sell | 172,585 | $9.33 | $1.61M | 3,606 |
| May 3, 2023↗ | Carruthers R Michael | Chief Financial Officer | Sell | 1,336 | $8.90 | $11.9K | 16,126 |
| May 3, 2023↗ | Derakhshan Behrad | Chief Business Officer | Sell | 1,747 | $8.90 | $15.6K | 7,020 |
| May 3, 2023↗ | Donovan Joanne M. | CMO | Sell | 3,254 | $8.90 | $29.0K | 9,960 |
| May 3, 2023↗ | KOCH KEVIN | President and CEO | Sell | 3,203 | $8.90 | $28.5K | 7,213 |
| May 3, 2023↗ | MOORE JOHN R | General Counsel | Sell | 1,897 | $8.90 | $16.9K | 6,565 |
| May 3, 2023↗ | Russell Alan J | Chief Scientific Officer | Sell | 1,602 | $8.90 | $14.3K | 176,191 |
| Oct 5, 2022↗ | MOORE JOHN R | General Counsel | Sell | 4,730 | $9.76 | $46.2K | 3,000 |
| Sep 16, 2022↗ | Novo Holdings A/S | 10% Owner | Buy | 484,496 | $10.32 | $5.00M | 6,071,700 |
| Sep 16, 2022↗ | ORBIMED ADVISORS LLC | Director | Buy | 484,496 | $10.32 | $5.00M | 13,982,000 |
| Sep 16, 2022↗ | Thompson Peter A. | Director | Buy | 484,496 | $10.32 | $5.00M | 13,982,000 |
| Sep 8, 2022↗ | MOORE JOHN R | General Counsel | Sell | 4,730 | $10.91 | $51.6K | 5,351 |
| Aug 5, 2022↗ | MOORE JOHN R | General Counsel | Sell | 9,232 | $9.31 | $85.9K | 3,000 |
| Jul 7, 2022↗ | MOORE JOHN R | General Counsel | Sell | 9,232 | $8.37 | $77.3K | 3,000 |
| Jun 21, 2022↗ | MOORE JOHN R | General Counsel | Sell | 67,927 | $6.83 | $463.9K | 3,000 |
| Jun 15, 2022↗ | MOORE JOHN R | General Counsel | Sell | 26,381 | $6.08 | $160.5K | 21,075 |
| Jun 10, 2022↗ | MOORE JOHN R | General Counsel | Sell | 27,306 | $6.44 | $175.9K | 3,000 |
| Jun 7, 2022↗ | MOORE JOHN R | General Counsel | Sell | 47,287 | $6.26 | $296.0K | 3,000 |
| May 20, 2022↗ | ORBIMED ADVISORS LLC | Director | Buy | 138,000 | $7.21 | $995.0K | 13,497,500 |
| May 20, 2022↗ | Thompson Peter A. | Director | Buy | 138,000 | $7.21 | $995.0K | 13,497,500 |
| May 18, 2022↗ | MOORE JOHN R | General Counsel | Sell | 10,800 | $7.42 | $80.1K | 3,000 |
| Nov 17, 2021↗ | Russell Alan J | Chief Scientific Officer | Sell | 479 | $19.11 | $9.2K | 38 |
| Nov 12, 2021↗ | Russell Alan J | Chief Scientific Officer | Sell | 69,740 | $19.91 | $1.39M | 53,355 |
| Nov 8, 2021↗ | Russell Alan J | Chief Scientific Officer | Sell | 29,451 | $19.82 | $583.8K | 92,278 |
| Nov 3, 2021↗ | Russell Alan J | Chief Scientific Officer | Sell | 44,172 | $17.88 | $789.9K | 143,373 |
| Oct 18, 2021↗ | Russell Alan J | Chief Scientific Officer | Sell | 7,182 | $18.17 | $130.5K | 145,275 |
| Oct 13, 2021↗ | Russell Alan J | Chief Scientific Officer | Sell | 1,270 | $18.02 | $22.9K | 151,024 |
| Oct 8, 2021↗ | Russell Alan J | Chief Scientific Officer | Sell | 21,028 | $18.39 | $386.7K | 171,214 |
| Oct 5, 2021↗ | Russell Alan J | Chief Scientific Officer | Sell | 5,778 | $18.24 | $105.4K | 178,826 |
| Sep 30, 2021↗ | Russell Alan J | Chief Scientific Officer | Sell | 26,454 | $17.10 | $452.5K | 190,944 |
| Sep 27, 2021↗ | Russell Alan J | Chief Scientific Officer | Sell | 58,546 | $18.30 | $1.07M | 242,337 |
| Mar 31, 2021↗ | Novo Holdings A/S | 10% Owner | Buy | 625,000 | $16.00 | $10.00M | 5,587,210 |
| Mar 31, 2021↗ | ORBIMED ADVISORS LLC | Director | Buy | 359,375 | $16.00 | $5.75M | 13,359,500 |
| Mar 31, 2021↗ | ROOT JONATHAN D | Director | Buy | 15,625 | $16.00 | $250.0K | 15,625 |
| Mar 31, 2021↗ | Thompson Peter A. | Director | Buy | 359,375 | $16.00 | $5.75M | 13,359,500 |
| Mar 30, 2021↗ | Flynn James E | 10% Owner | Buy | 625,000 | $16.00 | $10.00M | 3,933,140 |
EWTX Insider Buying Activity
The following table shows recent insider purchases of Edgewise Therapeutics, Inc. (EWTX) stock reported via SEC Form 4 filings.
| Date | Insider | Role | Type | Shares | Avg Price | Value | Shares After |
|---|---|---|---|---|---|---|---|
| Nov 11, 2025↗ | Fox Jonathan C | Director | Buy | 10,700 | $18.64 | $199.4K | 0 |
| Apr 3, 2025↗ | Thompson Peter A. | Director | Buy | 496,771 | $20.13 | $10.00M | 0 |
| Jan 25, 2024↗ | ORBIMED ADVISORS LLC | Director | Buy | 454,545 | $11.00 | $5.00M | 14,436,500 |
| Jan 25, 2024↗ | Thompson Peter A. | Director | Buy | 454,545 | $11.00 | $5.00M | 14,436,500 |
| Dec 28, 2023↗ | Fox Jonathan C | Buy | 10,857 | $9.30 | $101.0K | 10,857 | |
| Sep 16, 2022↗ | Novo Holdings A/S | 10% Owner | Buy | 484,496 | $10.32 | $5.00M | 6,071,700 |
| Sep 16, 2022↗ | ORBIMED ADVISORS LLC | Director | Buy | 484,496 | $10.32 | $5.00M | 13,982,000 |
| Sep 16, 2022↗ | Thompson Peter A. | Director | Buy | 484,496 | $10.32 | $5.00M | 13,982,000 |
| May 20, 2022↗ | ORBIMED ADVISORS LLC | Director | Buy | 138,000 | $7.21 | $995.0K | 13,497,500 |
| May 20, 2022↗ | Thompson Peter A. | Director | Buy | 138,000 | $7.21 | $995.0K | 13,497,500 |
| Mar 31, 2021↗ | Novo Holdings A/S | 10% Owner | Buy | 625,000 | $16.00 | $10.00M | 5,587,210 |
| Mar 31, 2021↗ | ORBIMED ADVISORS LLC | Director | Buy | 359,375 | $16.00 | $5.75M | 13,359,500 |
| Mar 31, 2021↗ | ROOT JONATHAN D | Director | Buy | 15,625 | $16.00 | $250.0K | 15,625 |
| Mar 31, 2021↗ | Thompson Peter A. | Director | Buy | 359,375 | $16.00 | $5.75M | 13,359,500 |
| Mar 30, 2021↗ | Flynn James E | 10% Owner | Buy | 625,000 | $16.00 | $10.00M | 3,933,140 |
EWTX Insider Selling Activity
The following table shows recent insider sales of Edgewise Therapeutics, Inc. (EWTX) stock reported via SEC Form 4 filings.
| Date | Insider | Role | Type | Shares | Avg Price | Value | Shares After |
|---|---|---|---|---|---|---|---|
| Jan 23, 2026↗ | Edris Badreddin | director | Sell | 115,471 | $29.44 | $3.40M | 121,601 |
| Jan 21, 2026↗ | Edris Badreddin | Director | Sell | 115,471 | $29.44 | $3.40M | 0 |
| Nov 12, 2025↗ | Russell Alan J | Chief Scientific Officer | Sell | 100,000 | $21.12 | $2.11M | 0 |
| Aug 26, 2025↗ | Russell Alan J | Chief Scientific Officer | Sell | 100,000 | $14.60 | $1.46M | 0 |
| Aug 12, 2025↗ | Carruthers R Michael | Chief Financial Officer | Sell | 1,428 | $13.39 | $19.1K | 0 |
| Aug 12, 2025↗ | Derakhshan Behrad | Chief Business Officer | Sell | 2,491 | $13.39 | $33.4K | 0 |
| Aug 12, 2025↗ | Donovan Joanne M. | CMO | Sell | 2,862 | $13.39 | $38.3K | 0 |
| Aug 12, 2025↗ | KOCH KEVIN | President and CEO | Sell | 7,972 | $13.39 | $106.8K | 0 |
| Aug 12, 2025↗ | MOORE JOHN R | General Counsel | Sell | 2,098 | $13.39 | $28.1K | 0 |
| Aug 12, 2025↗ | Russell Alan J | Chief Scientific Officer | Sell | 1,907 | $13.39 | $25.5K | 0 |
| May 1, 2025↗ | Carruthers R Michael | Chief Financial Officer | Sell | 1,314 | $16.45 | $21.6K | 0 |
| May 1, 2025↗ | Derakhshan Behrad | Chief Business Officer | Sell | 1,691 | $16.45 | $27.8K | 0 |
| May 1, 2025↗ | Donovan Joanne M. | CMO | Sell | 5,187 | $16.45 | $85.3K | 0 |
| May 1, 2025↗ | KOCH KEVIN | President and CEO | Sell | 4,276 | $16.45 | $70.4K | 0 |
| May 1, 2025↗ | MOORE JOHN R | General Counsel | Sell | 1,930 | $16.45 | $31.8K | 0 |
| May 1, 2025↗ | Russell Alan J | Chief Scientific Officer | Sell | 1,551 | $16.45 | $25.5K | 0 |
| Mar 7, 2025↗ | KOCH KEVIN | President and CEO | Sell | 100 | $30.00 | $3.0K | 0 |
| Mar 7, 2025↗ | Russell Alan J | Chief Scientific Officer | Sell | 200 | $30.02 | $6.0K | 0 |
| Feb 7, 2025↗ | Derakhshan Behrad | Chief Business Officer | Sell | 10,000 | $30.03 | $300.3K | 16,837 |
| Feb 7, 2025↗ | KOCH KEVIN | President and CEO | Sell | 9,536 | $30.13 | $287.3K | 14,478 |
| Feb 7, 2025↗ | Russell Alan J | Chief Scientific Officer | Sell | 9,215 | $30.04 | $276.8K | 14,863 |
| Jan 30, 2025↗ | Donovan Joanne M. | CMO | Sell | 25,000 | $27.63 | $690.7K | 16,358 |
| Dec 31, 2024↗ | Russell Alan J | Chief Scientific Officer | Sell | 100,000 | $27.37 | $2.74M | 14,863 |
| Dec 27, 2024↗ | Semigran Marc | Chief Development Officer | Sell | 29,709 | $29.69 | $881.9K | 8,445 |
| Sep 24, 2024↗ | Carruthers R Michael | Chief Financial Officer | Sell | 125,092 | $28.57 | $3.57M | 35,928 |
| Sep 24, 2024↗ | Derakhshan Behrad | Chief Business Officer | Sell | 42,068 | $29.03 | $1.22M | 15,121 |
| Sep 24, 2024↗ | Donovan Joanne M. | CMO | Sell | 7,162 | $28.29 | $202.6K | 14,538 |
| Sep 24, 2024↗ | MOORE JOHN R | General Counsel | Sell | 70,922 | $28.15 | $2.00M | 3,252 |
| Sep 24, 2024↗ | Russell Alan J | Chief Scientific Officer | Sell | 75,000 | $28.27 | $2.12M | 13,534 |
| May 3, 2024↗ | Carruthers R Michael | Chief Financial Officer | Sell | 2,157 | $18.91 | $40.8K | 35,230 |
| May 3, 2024↗ | Derakhshan Behrad | Chief Business Officer | Sell | 1,718 | $18.91 | $32.5K | 13,422 |
| May 3, 2024↗ | Donovan Joanne M. | CMO | Sell | 3,682 | $18.91 | $69.6K | 19,897 |
| May 3, 2024↗ | KOCH KEVIN | President and CEO | Sell | 3,152 | $18.91 | $59.6K | 14,478 |
| May 3, 2024↗ | MOORE JOHN R | General Counsel | Sell | 1,956 | $18.91 | $37.0K | 3,252 |
| May 3, 2024↗ | Russell Alan J | Chief Scientific Officer | Sell | 1,576 | $18.91 | $29.8K | 7,238 |
| Feb 9, 2024↗ | Derakhshan Behrad | Chief Business Officer | Sell | 10,000 | $20.03 | $200.3K | 7,020 |
| Feb 9, 2024↗ | MOORE JOHN R | General Counsel | Sell | 29,835 | $20.00 | $596.8K | 0 |
| Jan 25, 2024↗ | Carruthers R Michael | Chief Financial Officer | Sell | 90,000 | $15.78 | $1.42M | 29,024 |
| Dec 28, 2023↗ | MOORE JOHN R | General Counsel | Sell | 8,497 | $10.50 | $89.2K | 0 |
| Dec 28, 2023↗ | Russell Alan J | Chief Scientific Officer | Sell | 172,585 | $9.33 | $1.61M | 3,606 |
| May 3, 2023↗ | Carruthers R Michael | Chief Financial Officer | Sell | 1,336 | $8.90 | $11.9K | 16,126 |
| May 3, 2023↗ | Derakhshan Behrad | Chief Business Officer | Sell | 1,747 | $8.90 | $15.6K | 7,020 |
| May 3, 2023↗ | Donovan Joanne M. | CMO | Sell | 3,254 | $8.90 | $29.0K | 9,960 |
| May 3, 2023↗ | KOCH KEVIN | President and CEO | Sell | 3,203 | $8.90 | $28.5K | 7,213 |
| May 3, 2023↗ | MOORE JOHN R | General Counsel | Sell | 1,897 | $8.90 | $16.9K | 6,565 |
| May 3, 2023↗ | Russell Alan J | Chief Scientific Officer | Sell | 1,602 | $8.90 | $14.3K | 176,191 |
| Oct 5, 2022↗ | MOORE JOHN R | General Counsel | Sell | 4,730 | $9.76 | $46.2K | 3,000 |
| Sep 8, 2022↗ | MOORE JOHN R | General Counsel | Sell | 4,730 | $10.91 | $51.6K | 5,351 |
| Aug 5, 2022↗ | MOORE JOHN R | General Counsel | Sell | 9,232 | $9.31 | $85.9K | 3,000 |
| Jul 7, 2022↗ | MOORE JOHN R | General Counsel | Sell | 9,232 | $8.37 | $77.3K | 3,000 |
| Jun 21, 2022↗ | MOORE JOHN R | General Counsel | Sell | 67,927 | $6.83 | $463.9K | 3,000 |
| Jun 15, 2022↗ | MOORE JOHN R | General Counsel | Sell | 26,381 | $6.08 | $160.5K | 21,075 |
| Jun 10, 2022↗ | MOORE JOHN R | General Counsel | Sell | 27,306 | $6.44 | $175.9K | 3,000 |
| Jun 7, 2022↗ | MOORE JOHN R | General Counsel | Sell | 47,287 | $6.26 | $296.0K | 3,000 |
| May 18, 2022↗ | MOORE JOHN R | General Counsel | Sell | 10,800 | $7.42 | $80.1K | 3,000 |
| Nov 17, 2021↗ | Russell Alan J | Chief Scientific Officer | Sell | 479 | $19.11 | $9.2K | 38 |
| Nov 12, 2021↗ | Russell Alan J | Chief Scientific Officer | Sell | 69,740 | $19.91 | $1.39M | 53,355 |
| Nov 8, 2021↗ | Russell Alan J | Chief Scientific Officer | Sell | 29,451 | $19.82 | $583.8K | 92,278 |
| Nov 3, 2021↗ | Russell Alan J | Chief Scientific Officer | Sell | 44,172 | $17.88 | $789.9K | 143,373 |
| Oct 18, 2021↗ | Russell Alan J | Chief Scientific Officer | Sell | 7,182 | $18.17 | $130.5K | 145,275 |
| Oct 13, 2021↗ | Russell Alan J | Chief Scientific Officer | Sell | 1,270 | $18.02 | $22.9K | 151,024 |
| Oct 8, 2021↗ | Russell Alan J | Chief Scientific Officer | Sell | 21,028 | $18.39 | $386.7K | 171,214 |
| Oct 5, 2021↗ | Russell Alan J | Chief Scientific Officer | Sell | 5,778 | $18.24 | $105.4K | 178,826 |
| Sep 30, 2021↗ | Russell Alan J | Chief Scientific Officer | Sell | 26,454 | $17.10 | $452.5K | 190,944 |
| Sep 27, 2021↗ | Russell Alan J | Chief Scientific Officer | Sell | 58,546 | $18.30 | $1.07M | 242,337 |
EWTX Insiders
Similar Stocks to EWTX
VRTX
Vertex Pharmaceuticals Incorporated
$470.20-1.66%
$121.44B
REGN
Regeneron Pharmaceuticals, Inc.
$743.51-0.41%
$77.57B
ALNY
Alnylam Pharmaceuticals, Inc.
$313.45-1.19%
$42.07B
INSM
Insmed Incorporated
$139.06-0.33%
$30.07B
UTHR
United Therapeutics Corporation
$536.12+0.97%
$23.50B
MRNA
Moderna, Inc.
$52.56-1.89%
$20.76B
ROIV
Roivant Sciences Ltd.
$28.06-1.44%
$20.08B
RPRX
Royalty Pharma plc
$45.65-0.57%
$19.56B